Latest news on Alzheimer's

Check out the latest news about Alzheimer's disease research that we carry out at the Barcelonaβeta Brain Research Center (BBRC). Discover the advances in Alzheimer's prevention in which our scientists participate, as well as the news of the Alfa Study, dedicated to the early detection and prevention of the disease.

The research concludes that such markers aid in the early identification of individuals at risk of developing the disease

25 Jul | 2024

Müge Akıncı receives her PhD with a research on markers for the identification of preclinical Alzheimer's disease

The work focuses on the role of pathophysiological processes beyond amyloidosis and tauopathy, and modifiable risk factors in the early development of Alzheimer’s disease during its preclinical stage.

AAIC, the most important and influential conference focused on scientific advances in the field Alzheimer's and other dementias

23 Jul | 2024

The BBRC participates in AAIC 2024 with six talks and twenty posters

During the meeting, the teams will disseminate the news of their research in the international scientific community.

Dr. Michalis Kassinopoulos has been one of the main authors of the study

22 Jul | 2024

Cerebral blood flow decreases in asymptomatic stages of Alzheimer’s

This is one of the main conclusions of a study led by BBRC and published in Alzheimer’s and Dementia.

The results of the study indicate that preventive nutritional interventions could help improve brain function and prevent Alzheimer's-associated dementia

11 Jul | 2024

A diet rich in omega-3 fats may be key to preventing Alzheimer's

The research, based on data from 320 participants of the Alfa cohort, promoted by the ”la Caixa” Foundation, concludes that nutritional interventions could prevent the disease.

Donanemab joins the approval a year ago in the United States of another drug that also slowed down the cognitive deterioration caused by the disease, lecanemab

04 Jul | 2024

A new drug approved in the United States to treat the initial stages of Alzheimer's

The FDA has given the green light to donanemab, a monoclonal antibody that attacks amyloid protein plaques.

The document details the most salient activity of the two centers in 2023.

28 Jun | 2024

"We investigate, we move forward": the Pasqual Maragall Foundation and BBRC's Impact Report 2023 is now available

The document details the most salient activity of the two centers in 2023, a year marked by a major paradigm shift in the approach to Alzheimer's disease.